European Commission Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults



Janssen Global Services, LLC

BEERSE, BELGIUM, 23 November, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the approval of the long-acting atypical antipsychotic therapy BYANNLI® (6-monthly paliperidone palmitate; PP6M) by the European Commission (EC) for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1-monthly paliperidone palmitate (PP1M) or 3-monthly paliperidone palmitate (PP3M).1 The approval makes PP6M the first twice-yearly treatment for adults living with schizophrenia to be approved by the EC, with the longest available dosing interval for an antipsychotic medication in the European Economic Area.

Related News

ASEC Frontier (Thailand) Co., Ltd

Address : 1 Empire Tower, Unit 1509 15th floor South Sathorn road Yannawa Sathorn Bangkok, Thailand 10120

Tel : +662-118-0873

Email :

Website :


Contact Us